Catharine Mary Louise West

Prof. Catharine Mary Louise West

orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
FSFredrick Schumacher
Fredrick Schumacher
AOAli Amin Al Olama
Ali Amin Al Olama
SBSonja I. Berndt
Sonja I. Berndt
SBSara Benlloch
Sara Benlloch
MAMahbubl Ahmed
Mahbubl Ahmed
C(Cancer Of The Prostate In Sweden (Caps)
Cancer Of The Prostate In Sweden (Caps)
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10−8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10−9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10−9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55–2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04–6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1.

16 January 2009 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
GBGillian C. Barnett
Gillian C. Barnett
CWCatharine Mary Louise West
Catharine Mary Louise West
ADAlison M. Dunning
Alison M. Dunning
RERebecca M. Elliott
Rebecca M. Elliott
CCCharlotte E. Coles
Charlotte E. Coles
NBNeil G. Burnet
Neil G. Burnet

19 January 2010 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
FBFrancesca Buffa
Francesca Buffa
DFDavid Favara
David Favara
CWCatharine Mary Louise West
Catharine Mary Louise West
CMC J Miller
C J Miller
There is a need to develop robust and clinically applicable gene expression signatures. Hypoxia is a key factor promoting solid tumour progression and resistance to therapy; a hypoxia signature has the potential to be not only prognostic but also to predict benefit from particular interventions. An approach for deriving signatures that combine knowledge of gene function and analysis of in vivo co-expression patterns was used to define a common hypoxia signature from three head and neck and five breast cancer studies. Previously validated hypoxia-regulated genes (seeds) were used to generate hypoxia co-expression cancer networks. A common hypoxia signature, or metagene, was derived by selecting genes that were consistently co-expressed with the hypoxia seeds in multiple cancers. This was highly enriched for hypoxia-regulated pathways, and prognostic in multivariate analyses. Genes with the highest connectivity were also the most prognostic, and a reduced metagene consisting of a small number of top-ranked genes, including VEGFA, SLC2A1 and PGAM1, outperformed both a larger signature and reported signatures in independent data sets of head and neck, breast and lung cancers. Combined knowledge of multiple genes' function from in vitro experiments together with meta-analysis of multiple cancers can deliver compact and robust signatures suitable for clinical application.

4 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DCDavid V. Conti
David V. Conti
BDBurcu F. Darst
Burcu F. Darst
LMLilit C. Moss
Lilit C. Moss
ESEdward J. Saunders
Edward J. Saunders
XSXin Sheng
Xin Sheng
CHChristopher A. Haiman
Christopher A. Haiman

1 April 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SWStuart C Winter
Stuart C Winter
FBFrancesca Buffa
Francesca Buffa
PSPriyamal Silva
Priyamal Silva
CMCrispin Miller
Crispin Miller
HVHelen R. Valentine
Helen R. Valentine
DFDavid Favara
David Favara
Affymetrix U133plus2 GeneChips were used to profile 59 head and neck squamous cell cancers. A hypoxia metagene was obtained by analysis of genes whose in vivo expression clustered with the expression of 10 well-known hypoxia-regulated genes (e.g., CA9, GLUT1, and VEGF). To minimize random aggregation, strongly correlated up-regulated genes appearing in >50% of clusters defined a signature comprising 99 genes, of which 27% were previously known to be hypoxia associated. The median RNA expression of the 99 genes in the signature was an independent prognostic factor for recurrence-free survival in a publicly available head and neck cancer data set, outdoing the original intrinsic classifier. In a published breast cancer series, the hypoxia signature was a significant prognostic factor for overall survival independent of clinicopathologic risk factors and a trained profile. The work highlights the validity and potential of using data from analysis of in vitro stress pathways for deriving a biological metagene/gene signature in vivo. [Cancer Res 2007;67(7):3441–9]

16 December 2014 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
IFI N Fleming
I N Fleming
RMR Manavaki
R Manavaki
PBPhil Blower
Phil Blower
CWCatharine Mary Louise West
Catharine Mary Louise West
KWK J Williams
K J Williams
FGF J Gilbert
F J Gilbert
Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association with an aggressive tumour phenotype and therapeutic resistance. Given its prominent role in oncology, accurate detection of hypoxia is important, as it impacts on prognosis and could influence treatment planning. A variety of approaches have been explored over the years for detecting and monitoring changes in hypoxia in tumours, including biological markers and noninvasive imaging techniques. Positron emission tomography (PET) is the preferred method for imaging tumour hypoxia due to its high specificity and sensitivity to probe physiological processes in vivo, as well as the ability to provide information about intracellular oxygenation levels. This review provides an overview of imaging hypoxia with PET, with an emphasis on the advantages and limitations of the currently available hypoxia radiotracers.